Literature DB >> 8864525

The role of endogenous bradykinin in blood pressure homeostasis in spontaneously hypertensive rats.

H R Holte1, A Bjørnstad-Ostensen, T Berg.   

Abstract

1. The role of endogenous bradykinin in mean arterial blood pressure (BP) homeostasis was studied in spontaneously hypertensive (SHR) and normotensive (WKY) rats by the use of a bradykinin B2-receptor antagonist (BKant; Hoe 140, 11.6 micrograms kg-1) and converting enzyme (kininase II) inhibitor (captopril, 10 mg). To obtain a response to captopril that was induced through inhibition of kinin-degradation only and not through inhibition of angiotensin II-formation, the studies were performed on binephrectomized male rats to eliminate the renin-angiotensin system. 2. The role of the nitric oxide (NO) and the adrenergic systems were evaluated by the use of NO-synthase inhibitor (L-NAME, 0.3 g kg-1) and phentolamine (2 mg kg-1), respectively. 3. The rats were anaesthetized and pretreated with two injections of vehicle (PBS) or drugs spaced 5 min apart: PBS + PBS; BKant + PBS; PBS + L-NAME; BKant + L-NAME; or phentolamine + L-NAME. All rats were given captopril 15 min later. Time-control groups were treated with L-NAME but not captopril. 4. In WKY rats, captopril did not significantly alter BP in any of the groups. In the SHR-PBS + PBS group, on the other hand, captopril induced an immediate fall in BP (delta BP = -23 +/- 4 mmHg, P < 0.0017) which was completely blocked by BKant (delta BP = 2 +/- 2 mmHg) (P < 0.0011). L-NAME did not significantly alter the immediate hypotensive response to captopril but disclosed a later hypertensive reaction. In L-NAME + BKant-treated rats, both the hypotensive response and the late hypertension was abolished. In rats treated with phentolamine + L-NAME, the immediate fall in BP was not different from the controls whereas the late hypertension was absent. 5. BKant itself had no effect on basal BP in either WKY or SHR even when a 10 times higher dose was tested in a separate set of experiments. This was true also for conscious, nonnephrectomized SHR rats. 6. It was concluded that endogenous production of bradykinin was demonstrable through kininase II-inhibition in hypertensive but not in normotensive rats. However, this endogenous bradykinin did not play a role in basal BP homeostasis. The captopril-induced hypotension depended on kinin but, under the present conditions, not on NO as a mediator. The fall in BP induced a compensatory adrenergic hypertensive response which was revealed when the continuous NO-synthesis was blocked by L-NAME.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864525      PMCID: PMC1909879          DOI: 10.1111/j.1476-5381.1996.tb15626.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

2.  A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin.

Authors:  H Y Yang; E G Erdös; Y Levin
Journal:  Biochim Biophys Acta       Date:  1970-08-21

3.  Enzymatic activity of rat submandibular gland kallikrein released into blood.

Authors:  T Berg; L Johansen; K Nustad
Journal:  Am J Physiol       Date:  1985-12

4.  Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril.

Authors:  O A Carretero; S Miyazaki; A G Scicli
Journal:  Hypertension       Date:  1981 Jan-Feb       Impact factor: 10.190

5.  Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist.

Authors:  A Benetos; H Gavras; J M Stewart; R J Vavrek; S Hatinoglou; I Gavras
Journal:  Hypertension       Date:  1986-11       Impact factor: 10.190

6.  Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation.

Authors:  B J Whittle; J Lopez-Belmonte; D D Rees
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

Review 7.  Endothelium-derived hyperpolarizing factor(s) and the potentiation of kinins by converting enzyme inhibitors.

Authors:  J V Mombouli; P M Vanhoutte
Journal:  Am J Hypertens       Date:  1995-05       Impact factor: 2.689

8.  Nitric oxide release from the isolated guinea pig heart.

Authors:  M Kelm; J Schrader
Journal:  Eur J Pharmacol       Date:  1988-10-18       Impact factor: 4.432

9.  Hypertensive effect of a bradykinin antagonist in normotensive rats.

Authors:  A Benetos; I Gavras; H Gavras
Journal:  Hypertension       Date:  1986-11       Impact factor: 10.190

10.  Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension.

Authors:  L F Carbonell; O A Carretero; J M Stewart; A G Scicli
Journal:  Hypertension       Date:  1988-03       Impact factor: 10.190

View more
  1 in total

1.  The chronic blockade of angiotensin I-converting enzyme eliminates the sex differences of serum cytokine levels of spontaneously hypertensive rats.

Authors:  P L M Dalpiaz; A Z Lamas; I F Caliman; A R S Medeiros; G R Abreu; M R Moysés; T U Andrade; M F Alves; A K Carmona; N S Bissoli
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.